Home Updates Press Transasia Bio-Medicals Ltd. strengthens its foray into Immunoassay with the acquisition of Calbiotech Group of Companies, USA
Transasia Bio-Medicals Ltd. strengthens its foray into Immunoassay with the acquisition of Calbiotech Group of Companies, USA
Date: 29 April , 2017 in USA , USA

Transasia Bio-Medicals Ltd., India’s leading In-vitro diagnostic company, recently acquired Calbiotech Group of Companies, USA through its German subsidiary Erba Mannheim for 40 Million USD. This is the 14th overseas IVD acquisition by Transasia in the last eight years.

Calbiotech based in Spring Valley, California is the first company to introduce immunoassay kits in the United States to detect antibodies against Zika virus in human blood. It is also known to develop innovative products for the emerging markets. It has more than 200 products, distributed to more than 60 countries.

With this acquisition Transasia is all set to strengthen its foray into ELISA and CLIA assays for human and animal research, including specific assays for autoimmune disorders, cancer and infectious diseases. Over the years, Transasia has been meeting the needs of the emerging markets through innovative and cutting-edge technologies designed and developed at its global, state-of-the-art facilities.

Speaking on the occasion, Mr. Suresh Vazirani, Chairman & Managing Director, Transasia-Erba Group said, “Calbiotech Inc. and Dr. Noori Barka have developed an excellent range of immunoassay products that will complement our growing range of diagnostic products. Globally the immunology segment of the IVD Industry is valued at around US$ 15 billion. Calbiotech’s expertise in Immunoassay will allow us to strengthen our position in this high growth market and integrate their strong R&D programme to further enhance the product development strategy of the Transasia- Erba Group.”

About Transasia-Erba Group

Transasia Bio-Medicals Ltd. offers a comprehensive product portfolio spanning all specialties of diagnostics including biochemistry, hematology, immunoassay & blood banking, urinalysis, diabetes, critical care, coagulation, microbiology and molecular diagnostics. Along with its subsidiaries in Germany, France, Czech Republic, Russia, Turkey, UK and USA, Transasia now reaches out to millions in over 104 countries.

Constantly striving to better its best and innovating to serve customers better is one of the key growth drivers at the Transasia-Erba Group. With a dedicated team of experts the Group has created an impressive track record of successful projects. With manufacturing facilities in India, USA and Czech Republic the Group offers innovative products with latest technologies to meet the changing customer needs of both the developed and the developing markets.

For more information, please visit www.transasia.co.in

About Calbiotech

Calbiotech is a worldwide leader in immunoassay development and manufacturing.  It is the first company to introduce immunoassay kits in the United States to detect antibodies against Zika virus in human blood.

Calbiotech’s commitment to state-of-the-art technologies and automation helps ensure high-quality, stable, flexible, automation-ready, and cost effective products and services.It has more than 200 products, distributed to more than 60 countries.

The group operates under cGMP and ISO 13485 Standards in an FDA Registered Facility in San Diego, California.

For more information, please visit www.calbiotech.com

Subscribe here
Go
Stay Connected
Address
Mallaustrasse 69-73 68219
Mannheim, Germany
© 2016-2017, Erba Mannheim All Rights Reserved
Select Country
International
USA